HSBC Initiates Coverage On Gilead Sciences with Reduce Rating, Announces Price Target of $71
Portfolio Pulse from Benzinga Newsdesk
HSBC analyst Morten Herholdt has initiated coverage on Gilead Sciences with a Reduce rating and a price target of $71.
September 06, 2023 | 9:25 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
HSBC has initiated coverage on Gilead Sciences with a Reduce rating and a price target of $71, which may negatively impact the stock's performance.
HSBC's Reduce rating indicates that the analyst believes Gilead Sciences' stock is likely to underperform in the near term. The price target of $71, if lower than the current trading price, suggests that the analyst expects the stock's price to decrease. This news could lead to a negative sentiment among investors, potentially causing a decrease in the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100